ABSTRACT
Vascular calcification (VC) is considered a common pathological process in various vascular diseases. Accumulating studies have confirmed that VC is involved in the inflammatory response in heart disease, and SPP1+ macrophages play an important role in this process. In VC, studies have focused on the physiological and pathological functions of macrophages, such as pro-inflammatory or anti-inflammatory cytokines and pro-fibrotic vesicles. Additionally, macrophages and activated lymphocytes highly express SPP1 in atherosclerotic plaques, which promote the formation of fatty streaks and plaque development, and SPP1 is also involved in the calcification process of atherosclerotic plaques that results in heart failure, but the crosstalk between SPP1-mediated immune cells and VC has not been adequately addressed. In this review, we summarize the regulatory effect of SPP1 on VC in T cells, macrophages, and dendritic cells in different organs' VC, which could be a potential therapeutic target for VC.
Subject(s)
Macrophages , Osteopontin , Vascular Calcification , Animals , Humans , Dendritic Cells/immunology , Dendritic Cells/metabolism , Macrophages/immunology , Macrophages/metabolism , Osteopontin/metabolism , Plaque, Atherosclerotic/immunology , Plaque, Atherosclerotic/pathology , Plaque, Atherosclerotic/metabolism , T-Lymphocytes/immunology , T-Lymphocytes/metabolism , Vascular Calcification/immunology , Vascular Calcification/metabolism , Vascular Calcification/pathologyABSTRACT
AIMS: Uromodulin is produced exclusively in the kidney and secreted into both urine and blood. Serum levels of uromodulin are correlated with kidney function and reduced in chronic kidney disease (CKD) patients, but physiological functions of serum uromodulin are still elusive. This study investigated the role of uromodulin in medial vascular calcification, a key factor associated with cardiovascular events and mortality in CKD patients. METHODS AND RESULTS: Experiments were performed in primary human (HAoSMCs) and mouse (MOVAS) aortic smooth muscle cells, cholecalciferol overload and subtotal nephrectomy mouse models and serum from CKD patients. In three independent cohorts of CKD patients, serum uromodulin concentrations were inversely correlated with serum calcification propensity. Uromodulin supplementation reduced phosphate-induced osteo-/chondrogenic transdifferentiation and calcification of HAoSMCs. In human serum, pro-inflammatory cytokines tumour necrosis factor α (TNFα) and interleukin-1ß (IL-1ß) co-immunoprecipitated with uromodulin. Uromodulin inhibited TNFα and IL-1ß-induced osteo-/chondrogenic signalling and activation of the transcription factor nuclear factor kappa-light-chain-enhancer of activated ß cells (NF-kB) as well as phosphate-induced NF-kB-dependent transcriptional activity in HAoSMCs. In vivo, adeno-associated virus (AAV)-mediated overexpression of uromodulin ameliorated vascular calcification in mice with cholecalciferol overload. Conversely, cholecalciferol overload-induced vascular calcification was aggravated in uromodulin-deficient mice. In contrast, uromodulin overexpression failed to reduce vascular calcification during renal failure in mice. Carbamylated uromodulin was detected in serum of CKD patients and uromodulin carbamylation inhibited its anti-calcific properties in vitro. CONCLUSIONS: Uromodulin counteracts vascular osteo-/chondrogenic transdifferentiation and calcification, at least in part, through interference with cytokine-dependent pro-calcific signalling. In CKD, reduction and carbamylation of uromodulin may contribute to vascular pathology.
Subject(s)
Cell Transdifferentiation , Cytokines/metabolism , Inflammation Mediators/metabolism , Muscle, Smooth, Vascular/metabolism , Myocytes, Smooth Muscle/metabolism , Renal Insufficiency, Chronic/blood , Uromodulin/blood , Vascular Calcification/prevention & control , Adult , Aged , Animals , Aorta/immunology , Aorta/metabolism , Cell Transdifferentiation/drug effects , Cells, Cultured , Chondrogenesis , Cytokines/genetics , Disease Models, Animal , Female , Humans , Male , Mice, Inbred C57BL , Mice, Inbred DBA , Mice, Knockout , Middle Aged , Muscle, Smooth, Vascular/drug effects , Muscle, Smooth, Vascular/immunology , Myocytes, Smooth Muscle/drug effects , Myocytes, Smooth Muscle/immunology , Osteogenesis , Phenotype , Protein Carbamylation , Renal Insufficiency, Chronic/immunology , Signal Transduction , Uromodulin/genetics , Uromodulin/pharmacology , Vascular Calcification/blood , Vascular Calcification/immunology , Young AdultABSTRACT
Continuous stimulation of inflammation is harmful to tissues of an organism. Inflammatory mediators not only have an effect on metabolic and inflammatory bone diseases but also have an adverse effect on certain genetic and periodontal diseases associated with bone destruction. Inflammatory factors promote vascular calcification in various diseases. Vascular calcification is a pathological process similar to bone development, and vascular diseases play an important role in the loss of bone homeostasis. The NLRP3 inflammasome is an essential component of the natural immune system. It can recognize pathogen-related molecular patterns or host-derived dangerous signaling molecules, recruit, and activate the pro-inflammatory protease caspase-1. Activated caspase-1 cleaves the precursors of IL-1ß and IL-18 to produce corresponding mature cytokines or recognizes and cleaves GSDMD to mediate cell pyroptosis. In this review, we discuss the role of NLRP3 inflammasome in bone diseases and vascular calcification caused by sterile or non-sterile inflammation and explore potential treatments to prevent bone loss.
Subject(s)
Bone Diseases/immunology , Inflammasomes/immunology , Inflammation/immunology , NLR Family, Pyrin Domain-Containing 3 Protein/immunology , Vascular Calcification/immunology , Biomarkers/metabolism , Bone Diseases/metabolism , Humans , Inflammasomes/metabolism , Inflammation/metabolism , NLR Family, Pyrin Domain-Containing 3 Protein/metabolism , Vascular Calcification/metabolismABSTRACT
OBJECTIVE: Both periodontal disease and cardiovascular disease (CVD) are overrepresented in rheumatoid arthritis (RA). This study was undertaken to investigate the contribution of periodontal pathogens to CVD in RA. METHODS: RA patients underwent assessments of coronary artery calcification (CAC), carotid intima-media thickness and plaque, and ankle-brachial index via computed tomography, ultrasound, and Doppler ultrasound, respectively. Sera were assayed for antibodies targeting Porphyromonas gingivalis (Pg), Aggregatibacter actinomycetemcomitans serotype B (Aa), and Aa-derived leukotoxin A (LtxA). Associations of antibodies against these periodontal pathogens with measures of atherosclerosis were explored using generalized linear models. RESULTS: Among 197 RA patients, anti-Pg was detected in 72 patients (37%), anti-Aa in 41 patients (21%), and anti-LtxA in 84 patients (43%). Adjusting for relevant confounders and reported tooth loss, the mean CAC score was 90% higher in those with anti-Aa and/or anti-LtxA compared with those without either antibody (19 units versus 10 units; P = 0.033). The adjusted odds of CAC ≥100 units were 2.23-fold higher in those with anti-Aa and/or anti-LtxA compared with those without either antibody (P = 0.040). Anti-Aa and/or anti-LtxA seropositivity was significantly associated with all other assessed measures of atherosclerosis except carotid plaque. Anti-Pg was not associated with any measure of atherosclerosis. Higher swollen joint count was associated with CAC exclusively in the group with anti-Aa and/or anti-LtxA. CONCLUSION: Immunoreactivity against Aa and/or its major virulence factor LtxA was associated with atherosclerosis in multiple vascular beds of RA patients and amplified the effect of swollen joints on coronary atherosclerosis, suggesting a role for treatment/prevention of periodontal disease in the prevention of CVD in RA.
Subject(s)
Aggregatibacter actinomycetemcomitans/immunology , Antibodies, Bacterial/immunology , Arthritis, Rheumatoid/immunology , Atherosclerosis/immunology , Coronary Artery Disease/immunology , Porphyromonas gingivalis/immunology , Vascular Calcification/immunology , Aged , Arthritis, Rheumatoid/complications , Arthritis, Rheumatoid/diagnostic imaging , Atherosclerosis/complications , Atherosclerosis/diagnostic imaging , Carotid Intima-Media Thickness , Case-Control Studies , Coronary Artery Disease/complications , Coronary Artery Disease/diagnostic imaging , Female , Humans , Male , Middle Aged , Risk Factors , Severity of Illness Index , Tomography, X-Ray Computed , Ultrasonography, Doppler , Vascular Calcification/complications , Vascular Calcification/diagnostic imagingABSTRACT
The human cationic anti-microbial peptide LL-37 is a T cell self-antigen in patients with psoriasis, who have increased risk of cardiovascular events. However, the role of LL-37 as a T cell self-antigen in the context of atherosclerosis remains unclear. The objective of this study was to test for the presence of T cells reactive to LL-37 in patients with acute coronary syndrome (ACS). Furthermore, the role of T cells reactive to LL-37 in atherosclerosis was assessed using apoE-/- mice immunized with the LL-37 mouse ortholog, mCRAMP. Peripheral blood mononuclear cells (PBMCs) from patients with ACS were stimulated with LL-37. PBMCs from stable coronary artery disease (CAD) patients or self-reported subjects served as controls. T cell memory responses were analyzed with flow cytometry. Stimulation of PBMCs with LL-37 reduced CD8+ effector T cell responses in controls and patients with stable CAD but not in ACS and was associated with reduced programmed cell death protein 1 (PDCD1) mRNA expression. For the mouse studies, donor apoE-/- mice were immunized with mCRAMP or adjuvant as controls, then T cells were isolated and adoptively transferred into recipient apoE-/- mice fed a Western diet. Recipient mice were euthanized after 5 weeks. Whole aortas and hearts were collected for analysis of atherosclerotic plaques. Spleens were collected for flow cytometric and mRNA expression analysis. Adoptive transfer experiments in apoE-/- mice showed a 28% reduction in aortic plaque area in mCRAMP T cell recipient mice (P < 0.05). Fifty six percent of adjuvant T cell recipient mice showed calcification in atherosclerotic plaques, compared to none in the mCRAMP T cell recipient mice (Fisher's exact test P = 0.003). Recipients of T cells from mice immunized with mCRAMP had increased IL-10 and IFN-γ expression in CD8+ T cells compared to controls. In conclusion, the persistence of CD8+ effector T cell response in PBMCs from patients with ACS stimulated with LL-37 suggests that LL-37-reactive T cells may be involved in the acute event. Furthermore, studies in apoE-/- mice suggest that T cells reactive to mCRAMP are functionally active in atherosclerosis and may be involved in modulating plaque calcification.
Subject(s)
Acute Coronary Syndrome/immunology , Antimicrobial Cationic Peptides/immunology , Aorta/immunology , Aortic Diseases/immunology , Atherosclerosis/immunology , Autoantigens/immunology , Leukocytes, Mononuclear/immunology , T-Lymphocytes/immunology , Vascular Calcification/immunology , Acute Coronary Syndrome/metabolism , Adoptive Transfer , Animals , Antimicrobial Cationic Peptides/pharmacology , Aorta/metabolism , Aorta/pathology , Aortic Diseases/metabolism , Aortic Diseases/pathology , Aortic Diseases/prevention & control , Atherosclerosis/metabolism , Atherosclerosis/pathology , Atherosclerosis/prevention & control , Autoantigens/pharmacology , Case-Control Studies , Cells, Cultured , Disease Models, Animal , Humans , Immunologic Memory , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/metabolism , Lymphocyte Activation , Male , Mice, Knockout, ApoE , T-Lymphocytes/drug effects , T-Lymphocytes/metabolism , T-Lymphocytes/transplantation , Vascular Calcification/metabolism , Vascular Calcification/pathology , Vascular Calcification/prevention & control , CathelicidinsABSTRACT
Generalized arterial calcification of infancy (GACI) and pseudoxanthoma elasticum (PXE) are characterized by pathologic calcifications in the media of large- and medium sized arteries. GACI is associated with biallelic mutations in ENPP1 in the majority of cases, whereas mutations in ABCC6 are known to cause PXE. Different treatment approaches including bisphosphonates and orally administered pyrophosphate (PPi) were investigated in recent years, but reversion of calcification could not be achieved. With this study, we pursued the idea of a combination of controlled drug delivery through nanoparticles and active targeting via antibody conjugation to develop a treatment for GACI and PXE. To establish a suitable drug delivery system, the chelating drug diethylenetriamine pentaacetic acid (DTPA) was conjugated to nanoparticles composed of human serum albumin (HSA) as biodegradable and non-toxic particle matrix. To accomplish an active targeting of the elastic fibers exposed through calcification of the affected areas, the nanoparticle surface was functionalized with an anti-elastin antibody. Cytotoxicity and cell interaction studies revealed favorable preconditions for the intended i.v. application. The chelating ability was evaluated in vitro and ex vivo on aortic ring culture isolated from two mouse models of GACI and PXE. The positive results led to the conclusion that the produced nanoparticles might be a promising therapy in the treatment of GACI and PXE.
Subject(s)
Antibodies/chemistry , Aorta/drug effects , Calcium Chelating Agents/pharmacology , Drug Carriers , Elastin/immunology , Pentetic Acid/pharmacology , Pseudoxanthoma Elasticum/drug therapy , Serum Albumin, Human/chemistry , Vascular Calcification/drug therapy , Animals , Antibodies/immunology , Aorta/immunology , Aorta/metabolism , Aorta/pathology , Calcium Chelating Agents/chemistry , Cell Line , Drug Compounding , Female , Humans , Male , Mice, Inbred C57BL , Mice, Knockout , Multidrug Resistance-Associated Proteins/deficiency , Multidrug Resistance-Associated Proteins/genetics , Nanoparticles , Pentetic Acid/chemistry , Pseudoxanthoma Elasticum/immunology , Pseudoxanthoma Elasticum/metabolism , Pseudoxanthoma Elasticum/pathology , Serum Albumin, Human/metabolism , Vascular Calcification/immunology , Vascular Calcification/metabolism , Vascular Calcification/pathologyABSTRACT
BACKGROUNDS: Type I interferonopathy is a group of autoinflammatory disorders associated with prominent enhanced type I interferon signaling. The mechanisms are complex, and the clinical phenotypes are diverse. This review briefly summarized the recent progresses of type I interferonopathy focusing on the clinical and molecular features, pathogeneses, diagnoses and potential therapies. DATA SOURCES: Original research articles and literature reviews published in PubMed-indexed journals. RESULTS: Type I interferonopathies include Aicardi-Goutières syndrome, spondyloenchondro-dysplasia with immune dysregulation, stimulator of interferon genes-associated vasculopathy with onset in infancy, X-linked reticulate pigmentary disorder, ubiquitin-specific peptidase 18 deficiency, chronic atypical neutrophilic dermatitis with lipodystrophy, and Singleton-Merten syndrome originally. Other disorders including interferon-stimulated gene 15 deficiency and DNAse II deficiency are believed to be interferonopathies as well. Intracranial calcification, skin vasculopathy, interstitial lung disease, failure to thrive, skeletal development problems and autoimmune features are common. Abnormal responses to nucleic acid stimuli and defective regulation of protein degradation are main mechanisms in disease pathogenesis. First generation Janus kinase inhibitors including baricitinib, tofacitinib and ruxolitinib are useful for disease control. Reverse transcriptase inhibitors seem to be another option for Aicardi-Goutières syndrome. CONCLUSIONS: Tremendous progress has been made for the discovery of type I interferonopathies and responsible genes. Janus kinase inhibitors and other agents have potential therapeutic roles. Future basic, translational and clinical studies towards disease monitoring and powerful therapies are warranted.
Subject(s)
Autoimmune Diseases/drug therapy , Autoimmune Diseases/immunology , Interferon Type I/immunology , Aortic Diseases/drug therapy , Aortic Diseases/genetics , Aortic Diseases/immunology , Autoimmune Diseases/genetics , Autoimmune Diseases of the Nervous System/drug therapy , Autoimmune Diseases of the Nervous System/genetics , Autoimmune Diseases of the Nervous System/immunology , Child , Dental Enamel Hypoplasia/drug therapy , Dental Enamel Hypoplasia/genetics , Dental Enamel Hypoplasia/immunology , Humans , Immunosuppressive Agents/therapeutic use , Interferon Type I/genetics , Metacarpus/abnormalities , Metacarpus/immunology , Muscular Diseases/drug therapy , Muscular Diseases/genetics , Muscular Diseases/immunology , Nervous System Malformations/drug therapy , Nervous System Malformations/genetics , Nervous System Malformations/immunology , Odontodysplasia/drug therapy , Odontodysplasia/genetics , Odontodysplasia/immunology , Osteoporosis/drug therapy , Osteoporosis/genetics , Osteoporosis/immunology , Phenotype , Protein Kinase Inhibitors/therapeutic use , Reverse Transcriptase Inhibitors/therapeutic use , Vascular Calcification/drug therapy , Vascular Calcification/genetics , Vascular Calcification/immunologyABSTRACT
Duchenne muscular dystrophy (DMD) causes severe disability and death of young men because of progressive muscle degeneration aggravated by sterile inflammation. DMD is also associated with cognitive and bone-function impairments. This complex phenotype results from the cumulative loss of a spectrum of dystrophin isoforms expressed from the largest human gene. Although there is evidence for the loss of shorter isoforms having impact in the central nervous system, their role in muscle is unclear. We found that at 8 weeks, the active phase of pathology in dystrophic mice, dystrophin-null mice (mdxßgeo) presented with a mildly exacerbated phenotype but without an earlier onset, increased serum creatine kinase levels, or decreased muscle strength. However, at 12 months, mdxßgeo diaphragm strength was lower, whereas fibrosis increased, compared with mdx. The most striking features of the dystrophin-null phenotype were increased ectopic myofiber calcification and altered macrophage infiltration patterns, particularly the close association of macrophages with calcified fibers. Ectopic calcification had the same temporal pattern of presentation and resolution in mdxßgeo and mdx muscles, despite significant intensity differences across muscle groups. Comparison of the rare dystrophin-null patients against those with mutations affecting full-length dystrophins may provide mechanistic insights for developing more effective treatments for DMD.
Subject(s)
Calcinosis/pathology , Dystrophin/metabolism , Fibrosis/pathology , Macrophages/immunology , Muscular Dystrophy, Animal/pathology , Muscular Dystrophy, Duchenne/pathology , Vascular Calcification/pathology , Animals , Calcinosis/immunology , Calcinosis/metabolism , Dystrophin/genetics , Fibrosis/immunology , Fibrosis/metabolism , Inflammation , Macrophages/metabolism , Male , Mice , Mice, Inbred mdx , Muscle, Skeletal/immunology , Muscle, Skeletal/metabolism , Muscle, Skeletal/pathology , Muscular Dystrophy, Animal/immunology , Muscular Dystrophy, Animal/metabolism , Muscular Dystrophy, Duchenne/immunology , Muscular Dystrophy, Duchenne/metabolism , Vascular Calcification/immunology , Vascular Calcification/metabolismABSTRACT
BACKGROUND: Vascular calcifications are associated with a high cardiovascular morbi-mortality in the coronary territory. In parallel, femoral arteries are more calcified and develop osteoid metaplasia (OM). This study was conducted to assess the predictive value of OM and local inflammation on the occurrence of mid- and long-term adverse cardiovascular events. METHOD: Between 2008 and 2015, 86 atheromatous samples were harvested during femoral endarterectomy on 81 patients and processed for histomorphological analyses of calcifications and inflammation (monocytes and B cells). Histological findings were compared with the long-term follow-up of patients, including major adverse cardiac event (MACE), major adverse limb event (MALE), and mortality. Frequencies were presented as percentage, and continuous data, as mean and standard deviation. A P-value < 0.05 was considered statistically significant. RESULTS: Median follow-up was 42.4 months (26.9-58.8). Twenty-eight percent of patients underwent a MACE; a MALE occurred in 18 (21%) limbs. Survival rate was 87.2% at 36 months. OM was found in 41 samples (51%), without any significant impact on the occurrence of MACE, MALE, or mortality. Preoperative white blood cell formulae revealed a higher rate of neutrophils associated with MACE (P = 0.04) and MALE (P = 0.0008), correlated with higher B cells counts in plaque samples. CONCLUSIONS: OM is part of femoral calcifications in almost 50% of the cases but does not seem to be an independent predictive variable for MACE or MALE. However, a higher rate of B cell infiltration of the plaque and preoperative neutrophil blood count may be predictive of adverse events during follow-up.
Subject(s)
Femoral Artery/pathology , Ossification, Heterotopic , Peripheral Arterial Disease/pathology , Vascular Calcification/pathology , Aged , Aged, 80 and over , Amputation, Surgical , B-Lymphocytes/immunology , B-Lymphocytes/pathology , Disease Progression , Endarterectomy , Female , Femoral Artery/immunology , Femoral Artery/surgery , France/epidemiology , Humans , Limb Salvage , Male , Middle Aged , Neutrophils/immunology , Neutrophils/pathology , Peripheral Arterial Disease/immunology , Peripheral Arterial Disease/mortality , Peripheral Arterial Disease/surgery , Plaque, Atherosclerotic , Reoperation , Retrospective Studies , Risk Factors , Time Factors , Treatment Outcome , Vascular Calcification/immunology , Vascular Calcification/mortality , Vascular Calcification/surgeryABSTRACT
The complement system plays an important role in cardiovascular disease in patients on hemodialysis. Vascular calcification is also one of the major causes of cardiovascular disease. We want to investigate the relationship between complement activation and vascular calcification in dialyzed patients. One hundred eight hemodialysis patients and 65 heathy controls were enrolled prospectively. Plasma C3a, C5a, mannose-binding lectin (MBL), and membrane attack complex (MAC or C5b-9) levels were detected using ELISA. Plasma C3c, fB, fH, C1q, and C4 levels were measured by immunity transmission turbidity. Abdominal aortic calcification (AAC) was measured by abdomen lateral plain radiograph, and the AAC score was calculated. We identified increased level of MBL and decreased level of C3c and complement factor B compared with normal control. However, C1q, complement factor H, and C4 levels remained at a similar level compared with individuals with normal renal function. The C3a and C5a levels increased, without change of MAC. Forty two of 108 HD patients had the AAC score. C3a levels were correlated with AAC score (r = 0.461, p = 0.002). The median C3a concentration was 238.72 (196.96, 323.41) ng/mL. When evaluated as AAC categories (≤ 4, > 5) with ordinal logistic regression, univariate analyses revealed that higher C3a levels were associated with severe AAC, while multivariate analyses adjusted for age, sex, and calcium level showed that higher C3a levels (OR, 6.28 (1.25-31.69); p = 0.03) were associated with severe AAC. The areas under the curve (AUC) for C3a to diagnose severe abdominal aortic calcification were 0.75(0.58-0.92, 0.01). The complement system was activated in patients on hemodialysis. Higher C3a levels are independently associated with severe AAC. Plasma C3a might have a diagnostic value for the severe AAC in HD patients.
Subject(s)
Aorta, Abdominal , Aortic Diseases/blood , Complement Activation , Complement C3/analysis , Kidney Failure, Chronic/therapy , Renal Dialysis , Vascular Calcification/blood , Adult , Aged , Aorta, Abdominal/diagnostic imaging , Aortic Diseases/diagnostic imaging , Aortic Diseases/immunology , Biomarkers/blood , Case-Control Studies , Cross-Sectional Studies , Female , Humans , Kidney Failure, Chronic/blood , Kidney Failure, Chronic/diagnosis , Kidney Failure, Chronic/immunology , Male , Middle Aged , Prospective Studies , Risk Factors , Severity of Illness Index , Up-Regulation , Vascular Calcification/diagnostic imaging , Vascular Calcification/immunologyABSTRACT
Decreased inflammation and cardiovascular mortality are evident in patients with end-stage chronic kidney disease treated by online hemodiafiltration. Extracellular vesicles (EV) are mediators of cell-to-cell communication and contain different RNA types. This study investigated whether mixed online hemodiafiltration (mOL-HDF) beneficial effects associate with changes in the RNA content of plasma EV in chronic kidney disease patients. Thirty bicarbonate hemodialysis (BHD) patients were randomized 1:1 to continue BHD or switch to mOL-HDF. Concentration, size, and microRNA content of plasma EV were evaluated for 9 mo; we then studied EV effects on inflammation, angiogenesis, and apoptosis of endothelial cells (HUVEC) and on osteoblast mineralization of vascular smooth muscle cells (VSMC). mOL-HDF treatment reduced different inflammatory markers, including circulating CRP, IL-6, and NGAL. All hemodialysis patients showed higher plasma levels of endothelial-derived EV than healthy subjects, with no significant differences between BHD and mOL-HDF. However, BHD-derived EV had an increased expression of the proatherogenic miR-223 with respect to healthy subjects or mOL-HDF. Compared with EV from healthy subjects, those from hemodialysis patients reduced angiogenesis and increased HUVEC apoptosis and VSMC calcification; however, all these detrimental effects were reduced with mOL-HDF with respect to BHD. Cell transfection with miR-223 mimic or antagomiR proved the role of this microRNA in EV-induced HUVEC and VSMC dysfunction. The switch from BHD to mOL-HDF significantly reduced systemic inflammation and miR-223 expression in plasma EV, thus improving HUVEC angiogenesis and reducing VSMC calcification.
Subject(s)
Endothelium, Vascular/immunology , Extracellular Vesicles , Gene Expression Regulation/immunology , Hemodiafiltration , MicroRNAs , Renal Insufficiency, Chronic , Uremia , Vascular Calcification , Adult , Aged , Endothelium, Vascular/metabolism , Endothelium, Vascular/pathology , Extracellular Vesicles/immunology , Extracellular Vesicles/metabolism , Female , Human Umbilical Vein Endothelial Cells , Humans , Inflammation/blood , Inflammation/immunology , Inflammation/pathology , Inflammation/therapy , Male , MicroRNAs/blood , MicroRNAs/immunology , Middle Aged , Renal Insufficiency, Chronic/blood , Renal Insufficiency, Chronic/immunology , Renal Insufficiency, Chronic/pathology , Renal Insufficiency, Chronic/therapy , Uremia/blood , Uremia/immunology , Uremia/pathology , Uremia/therapy , Vascular Calcification/blood , Vascular Calcification/immunology , Vascular Calcification/pathology , Vascular Calcification/therapyABSTRACT
AIMS: Smooth muscle cells (SMCs) play a role in medial vascular calcification, which can be stimulated by high levels of serum phosphate and inflammatory mediators. The aim of this study was to investigate whether mitogen-activated protein kinases (MAPKs) (p38 MAPK, ERK1/2, and JNK) and protein kinase A (PKA) can participate in inorganic phosphate (Pi)- and inflammation response-stimulated SMC calcification. MAIN METHODS: We examined the change of Pi- and/or inflammation-stimulated human aortic smooth muscle cell (HASMC) calcification in the presence and absence of inhibitors or small interfering RNAs. KEY FINDINGS: Ca levels were increased in HASMCs incubated with 1.5-3.9â¯mM Pi, but not with 0.9â¯mM Pi or compared with non-Pi-treated HASMCs. Furthermore, the addition of interferon-γ (IFN-γ) increased pro-inflammatory cytokines [interleukin (IL)-1α, IL-6, and tumor necrosis factor-α (TNF-α)] in media containing Raw 264.7 cells. Ca levels were significantly increased in HASMCs cultured in IFN-γ-treated medium, compared with non-IFN-γ-treated medium in the presence of Pi (0.9-2.4â¯mM). The inhibition of p38 MAPK and PKA decreased HASMC calcification stimulated by Pi and IFN-γ-treated medium, though PKA inhibition produced a more significant reduction in calcification than p38 MAPK inhibition. SIGNIFICANCE: These results indicate that PKA inhibition can efficiently reduce Pi- and inflammation-stimulated SMC calcification.
Subject(s)
Aorta/drug effects , Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors , Inflammation/physiopathology , Interferon-gamma/pharmacology , Muscle, Smooth, Vascular/drug effects , Phosphates/pharmacology , Vascular Calcification/drug therapy , Aorta/immunology , Aorta/metabolism , Aorta/pathology , Cells, Cultured , Humans , Inflammation Mediators/metabolism , Intracellular Signaling Peptides and Proteins/pharmacology , Muscle, Smooth, Vascular/immunology , Muscle, Smooth, Vascular/metabolism , Muscle, Smooth, Vascular/pathology , Tumor Necrosis Factor-alpha/metabolism , Vascular Calcification/immunology , Vascular Calcification/metabolism , Vascular Calcification/pathologyABSTRACT
Severe vascular calcification develops almost invariably in chronic kidney patients posing a substantial risk to quality of life and survival. This unmet medical need demands identification of novel therapeutic modalities. We aimed to pinpoint components of the uremic microenvironment triggering differentiation of vascular progenitors to calcifying osteoblast-like cells. In an unbiased approach, assessing the individual potency of 63 uremic retention solutes to enhance calcific phenotype conversion of vascular progenitor cells, the pro-inflammatory cytokines IL-1ß and TNF-α were identified as the strongest inducers followed by FGF-2, and PTH. Pharmacologic targeting of these molecules alone or in combination additively antagonized pro-calcifying properties of sera from uremic patients. Our findings stress the importance of pro-inflammatory cytokines above other characteristic components of the uremic microenvironment as key mediators of calcifying osteoblastic differentiation in vascular progenitors. Belonging to the group of "middle-sized molecules", they are neither effectively removed by conventional dialysis nor influenced by established supportive therapies. Specific pharmacologic interventions or novel extracorporeal approaches may help preserve regenerative capacity and control vascular calcification due to uremic environment.
Subject(s)
Anti-Inflammatory Agents/pharmacology , Cytokines/antagonists & inhibitors , Kidney Failure, Chronic/therapy , Uremia/therapy , Vascular Calcification/prevention & control , Adolescent , Anti-Inflammatory Agents/therapeutic use , Cell Differentiation/drug effects , Child , Child, Preschool , Cytokines/immunology , Female , Healthy Volunteers , Humans , Infant , Kidney Failure, Chronic/blood , Kidney Failure, Chronic/complications , Male , Mesenchymal Stem Cells/drug effects , Mesenchymal Stem Cells/physiology , Monocytes , Osteoblasts/physiology , Primary Cell Culture , Renal Dialysis , Uremia/blood , Uremia/immunology , Vascular Calcification/blood , Vascular Calcification/immunology , Young AdultABSTRACT
Cardiovascular disease (CVD) is the leading cause of mortality in patients with chronic kidney disease (CKD). Aortic stiffness, a nontraditional risk factor, is associated with high rate of mortality in CKD. Using a CKD animal model with medial vascular calcification, we previously reported increased mRNA expression of interleukin-6 (IL-6), tumor necrosis factor (TNF), and interleukin-1ß (IL-1ß) in calcified aorta. The aim of the study was to investigate the association between IL-6, TNF, IL-1ß, and aortic stiffness in end-stage renal disease patients. In a cross-sectional study, we enrolled 351 patients on dialysis. Aortic stiffness was assessed by carotid-femoral pulse wave velocity (cf-PWV), while central pulse pressure and augmentation index were assessed using generalized transfer function applied to the radial artery pressure wave form. Plasma IL-6, TNF, and IL-1ß were measured by enzyme-linked immunosorbent assay. IL-6 was associated with cf-PWV adjusted for mean blood pressure (MBP) (standardized ß = 0.270; P < .001). In a multivariate adjusted model for age, diabetes, hypertension, CVD, and MBP, IL-6 was still associated with cf-PWV (standardized ß = 0.096; P = .026). The impact of age, diabetes, and CVD on cf-PWV was partially mediated by IL-6 in a mediation analysis. However, there were no associations between TNF, IL-1ß, and aortic stiffness. While IL-6 was associated with augmentation index (standardized ß = 0.224; P < .001) and central pulse pressure (standardized ß = 0.162; P = .001) when adjusted for MBP and heart rate, this relationship was not significant after adjusting for potential confounders.This study suggests a potential role of IL-6 for CKD-related aortic stiffness.
Subject(s)
Interleukin-6/analysis , Kidney Failure, Chronic , Renal Dialysis , Vascular Calcification/immunology , Vascular Stiffness/immunology , Aged , Canada , Correlation of Data , Female , Hemodynamics , Humans , Inflammation/immunology , Kidney Failure, Chronic/diagnosis , Kidney Failure, Chronic/immunology , Kidney Failure, Chronic/physiopathology , Kidney Failure, Chronic/therapy , Male , Middle Aged , Pulse Wave Analysis , Renal Dialysis/methods , Renal Dialysis/statistics & numerical dataABSTRACT
Although soy phytoestrogen are proposed to prevent or improve postmenopausal vascular and bone diseases, the currently available data are controversial and unclear. In this study we evaluated the molecular and biochemical action of genistein on the cellular events involved in vascular calcification. Rat monocytes, aortic vascular cell and osteoblasts cultures in vitro exposed to Gen were employed. Gen down regulated the expression of cell adhesion molecules involved in stable leukocyte attachment. Using flow cytometry we found that the PE significantly diminished monocyte integrins CD11b, CD11c and CD18 expression either under basal and pro-inflammatory environment. At endothelial level, Gen also reduced Intercellular Adhesion Molecule 1 mRNA expression. On vascular muscle cells, the PE markedly reduced cell proliferation and migration. When vascular calcification was studied, muscle cells transdifferentiation into osteoblasts like cells was evaluated. Cells were cultured in osteogenic medium for 21 days. The expression of alkaline phosphatase and the presence of calcified nodules in the extracellular matrix were selected as features of muscle transdifferentiation. Calcified muscle cells exhibited higher levels of alkaline phosphatase activity and enhanced deposition of calcium nodules respect to native cells. Both osteoblastic markers were significantly reduced after Gen treatment. In contrast to this anti-osteogenic action, on bone cells Gen promoted osteoblasts growth, enhanced alkaline phosphatase activity and increased matrix mineralization. Its mitogenic action on osteoblasts directly depends on nitric oxide endothelial production stimulated by the PE. The data presented suppose a beneficial role of Gen on bone and vascular cells, with a cross link between both systems.
Subject(s)
Endothelium, Vascular/metabolism , Gene Expression Regulation , Genistein/metabolism , Monocytes/metabolism , Muscle, Smooth, Vascular/metabolism , Phytoestrogens/metabolism , Vascular Calcification/prevention & control , Animals , Animals, Newborn , Aorta , Biomarkers/metabolism , Cell Movement , Cell Proliferation , Cell Transdifferentiation , Cells, Cultured , Dietary Supplements , Endothelium, Vascular/cytology , Endothelium, Vascular/immunology , Endothelium, Vascular/pathology , Female , Genistein/therapeutic use , Intercellular Adhesion Molecule-1/chemistry , Intercellular Adhesion Molecule-1/genetics , Intercellular Adhesion Molecule-1/metabolism , Monocytes/cytology , Monocytes/immunology , Monocytes/pathology , Muscle, Smooth, Vascular/cytology , Muscle, Smooth, Vascular/immunology , Muscle, Smooth, Vascular/pathology , Osteoblasts/cytology , Osteoblasts/immunology , Osteoblasts/metabolism , Osteoblasts/pathology , Osteogenesis , Phytoestrogens/therapeutic use , Rats, Wistar , Skull , Vascular Calcification/immunology , Vascular Calcification/metabolism , Vascular Calcification/pathologyABSTRACT
In 1973, Singleton and Merten described a new syndrome in 2 female probands with aortic and cardiac valve calcifications, early loss of secondary dentition, and widened medullary cavities of the phalanges. In 1984, Aicardi and Goutières defined a phenotype resembling congenital viral infection with basal ganglia calcification and increased protein content in the cerebrospinal fluid. Between 2006 and 2012, mutations in 6 different genes were described to be associated with Aicardi-Goutières syndrome, specifically-TREX1, RNASEH2A, RNASEH2B, RNASEH2C, ADAR, and SAMHD1. More recently, mutations in IFIH1 were reported in a variety of neuroimmunological phenotypes, including Aicardi-Goutières syndrome, while a specific Arg822Gln mutation in IFIH1 was described in 3 discrete families with Singleton-Merten syndrome (SMS). IFIH1 encodes for melanoma differentiation-associated gene 5 (MDA5), and all mutations identified to date have been associated with an enhanced interferon response in affected individuals. In this study, we present a male child demonstrating recurrent febrile episodes, spasticity, and basal ganglia calcification suggestive of Aicardi-Goutières syndrome, who carries the same Arg822Gln mutation in IFIH1 previously associated with SMS. We conclude that both diseases are part of the interferonopathy grouping and that the Arg822Gln mutation in IFIH1 can cause a spectrum of disease, including neurological involvement.
Subject(s)
Aortic Diseases/immunology , Dental Enamel Hypoplasia/immunology , Inflammation/immunology , Interferon Type I/immunology , Interferon-Induced Helicase, IFIH1/immunology , Metacarpus/abnormalities , Muscular Diseases/immunology , Odontodysplasia/immunology , Osteoporosis/immunology , Vascular Calcification/immunology , Aortic Diseases/genetics , Child , Dental Enamel Hypoplasia/genetics , Humans , Interferon-Induced Helicase, IFIH1/genetics , Male , Metacarpus/immunology , Muscular Diseases/genetics , Mutation , Odontodysplasia/genetics , Osteoporosis/genetics , Vascular Calcification/geneticsABSTRACT
Circulating leukocyte subtypes and monocyte subsets are independent predictors of cardiovascular events. We hypothesized that an increased leukocyte subtype would predict severe coronary stenosis and extensive plaque involvement. We retrospectively analyzed clinical, laboratory, and coronary CT data in a total of 588 asymptomatic adults (69% men; mean age, 57 ± 9 years) undergoing a general health check-up. Intermediate CD14++CD16+ monocyte count had the strongest association with mixed and calcified plaque scores, whereas the numbers of neutrophils and classical CD14++CD16- monocytes were significantly associated with non-calcified plaque score. Only high CD14++CD16+ monocyte count (>12 cells/µL) significantly predicted extensive plaque involvement [odds ratio 3.16 (95% confidence interval 1.84-5.43), P < 0.001; quartile 4 vs. 1-3] and severe coronary stenosis [3.67 (1.84-7.33), P < 0.001; quartile 4 vs. 1-3] after adjustments for Framingham Risk Score (FRS), metabolic syndrome, and C-reactive protein. The CD14++CD16+ monocyte count, when added to FRS, significantly reclassified 30.4 and 26.7% of the overall and 50.2 and 36.2% of the intermediate-risk population (FRS 6-20%) for predicting extensive plaque involvement and severe coronary stenosis, respectively. Thus, in asymptomatic individuals, intermediate CD14++CD16+ monocyte could independently predict severe CAD and improve risk stratification.
Subject(s)
Computed Tomography Angiography , Coronary Angiography/methods , Coronary Stenosis/immunology , Coronary Vessels/diagnostic imaging , Lipopolysaccharide Receptors/blood , Monocytes/immunology , Multidetector Computed Tomography , Plaque, Atherosclerotic , Receptors, IgG/blood , Aged , Asymptomatic Diseases , Biomarkers/blood , Chi-Square Distribution , Coronary Stenosis/blood , Coronary Stenosis/diagnostic imaging , Female , GPI-Linked Proteins/blood , Humans , Leukocyte Count , Logistic Models , Male , Middle Aged , Multivariate Analysis , Odds Ratio , Predictive Value of Tests , Prognosis , Retrospective Studies , Risk Factors , Severity of Illness Index , Vascular Calcification/blood , Vascular Calcification/diagnostic imaging , Vascular Calcification/immunologyABSTRACT
Calcific aortic valve disease is a chronic inflammatory condition, and the inflammatory responses of aortic valve interstitial cells (AVICs) play a critical role in the disease progression. Double-stranded RNA (dsRNA) released from damaged or stressed cells is proinflammatory and may contribute to the mechanism of chronic inflammation observed in diseased aortic valves. The objective of this study is to determine the effect of dsRNA on AVIC inflammatory responses and the underlying mechanism. AVICs from normal human aortic valves were stimulated with polyinosinic-polycytidylic acid [poly(I:C)], a mimic of dsRNA. Poly(I:C) increased the production of IL-6, IL-8, monocyte chemoattractant protein-1, and ICAM-1. Poly(I:C) also induced robust activation of ERK1/2 and NF-κB. Knockdown of Toll-like receptor 3 (TLR3) or Toll-IL-1 receptor domain-containing adapter-inducing IFN-ß (TRIF) suppressed ERK1/2 and NF-κB p65 phosphorylation and reduced inflammatory mediator production induced by poly(I:C). Inhibition of NF-κB, not ERK1/2, reduced inflammatory mediator production in AVICs exposed to poly(I:C). Interestingly, inhibition of NF-κB by prevention of p50 migration failed to suppress inflammatory mediator production. NF-κB p65 intranuclear translocation induced by the TLR4 agonist was reduced by inhibition of p50 migration; however, poly(I:C)-induced p65 translocation was not, although the p65/p50 heterodimer is present in AVICs. Poly(I:C) upregulates the production of multiple inflammatory mediators through the TLR3-TRIF-NF-κB pathway in human AVICs. The NF-κB activated by dsRNA appears not to be the canonical p65/p50 heterodimers.
Subject(s)
Aortic Valve/immunology , Heart Valve Diseases/immunology , Inflammation Mediators/immunology , NF-kappa B/immunology , RNA, Double-Stranded/immunology , Vascular Calcification/immunology , Adaptor Proteins, Vesicular Transport/immunology , Aortic Valve/cytology , Cell Line , Humans , Signal Transduction/immunology , Toll-Like Receptor 3/immunology , Up-Regulation/immunologyABSTRACT
Vascular calcification (VC) is a highly regulated ectopic mineral deposition process involving immune cell infiltration in the vasculatures, which has been recognized to be promoted by hypertension. The matricellular glycoprotein osteopontin (OPN) is strongly induced in myeloid cells as a potential inflammatory mediator of vascular injury. This study aims to examine whether OPN is involved in the regulation of macrophage activation and osteoclast formation in hypertensive subjects with VC. We firstly found an increased proportion of CD11c+CD163- pro-inflammatory peripheral monocytes in hypertensive subjects with VC compared to those without VC by flow cytometric analysis. Primary cultured macrophages from hypertensive subjects with VC also showed altered expression profile of inflammatory factors and higher serum OPN level. Exogenous OPN promoted the differentiation of peripheral monocytes into an alternative, anti-inflammatory phenotype, and inhibited macrophage-to-osteoclast differentiation from these VC patients. In addition, calcified vessels showed increased osteoclasts accumulation accompanied with decreased macrophages infiltration in the of hypertensive subjects. Taken together, these demonstrated that OPN exerts an important role in the monocytes/macrophage phenotypic differentiation from hypertensive patients with VC, which includes reducing inflammatory factor expression and attenuating osteoclast formation.
Subject(s)
Hypertension/immunology , Inflammation Mediators/immunology , Macrophage Activation , Osteoclasts/immunology , Osteopontin/immunology , Vascular Calcification/immunology , Cell Differentiation , Cells, Cultured , Female , Humans , Hypertension/complications , Hypertension/metabolism , Inflammation Mediators/metabolism , Leukocytes, Mononuclear/immunology , Leukocytes, Mononuclear/metabolism , Male , Middle Aged , Osteoclasts/metabolism , Osteopontin/metabolism , RNA, Messenger/metabolism , Vascular Calcification/complications , Vascular Calcification/metabolismABSTRACT
OBJECTIVES: In rheumatoid arthritis (RA), the role of autoimmunity, especially anti-cyclic citrullinated peptide antibody (anti-CCP) level, and the time-course of left ventricular (LV) function is unknown. The objective was to assess LV function and the amount of coronary calcium in relation to anti-CCP levels in a cohort of treatment-naive RA patients, and to assess changes in these parameters during a 2 year follow-up period. METHOD: Sixty-six steroid- and disease-modifying anti-rheumatic drug-naive RA patients were treated with methotrexate according to the Danish national guidelines. We assessed LV function by conventional echocardiography and speckle-tracking echocardiography. We estimated the amount and progression of coronary calcium by coronary computed tomography. Patients were examined at the time of diagnosis and after 2 years. RESULTS: Patients with elevated anti-CCP at baseline and after 2 years, compared to those with non-persistently elevated anti-CCP, had significantly less improvement in S´ (1 ± 1.4 cm/s vs 0.2 ± 0.9 cm/s; p = 0.04) and a worsening in global longitudinal systolic strain (GLS) (0.6 ± 1.8% vs -1 ± 2.8%; p = 0.04). There was a significant correlation between ΔGLS over 2 years and anti-CCP at 2 year follow-up (r = 0.36; p = 0.006). We observed a small progression of coronary calcium score during the 2 year follow-up period. No differences in progression were found between patients with high anti-CCP titres at baseline and 2 year follow-up (n = 12) and patients with normal/low anti-CCP titres (n = 32) (23.8 ± 40.3 vs 22.6 ± 68.9; p = 0.96). CONCLUSIONS: Deformation analysis by speckle-tracking echocardiography is a valuable tool to detect early development of myocardial dysfunction despite normal ejection fraction in RA.